Link between PLA levels and sepsis heart failure severity
Part of Heart & circulation, Infections clinical trials.
This study looks at how levels of a substance called PLA relate to how severe sepsis-related heart failure is. It may help doctors understand your condition better and guide treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 50 and 90 years old.
- You must have been diagnosed with sepsis-related heart failure within the last 24 hours.
- Your SOFA score (a measure of illness severity) must be 2 or higher.
- You should not have other serious heart conditions like a recent heart attack or certain types of cardiomyopathy.
- You must not have severe liver or kidney failure that would affect your outlook.
- You must not be taking drugs that affect blood clotting or platelet function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a Chinese herbal formula called Yiqilishui in people with sepsis who have developed heart muscle weakness. It aims to see if the formula can help improve heart function.
This trial studies people with and without sepsis in the ICU to understand why some get very sick from infections. It aims to find better ways to predict who will have complications and guide treatment.
This study looks at whether a simple blood test can help doctors find out if ICU patients with infections are likely to develop sepsis within the next 48 hours. If you join, the researchers will measure a protein in your blood and follow you to see if you get sepsis.
This study looks at how checking heart function with an ultrasound during early sepsis treatment can help guide fluid and medication decisions. It may lead to better recovery by tailoring treatment to each patient's heart.
This study looks at how platelets (small cells that help blood clot) behave in people with severe infections (sepsis). It explores a specific part of the immune system (inflammasome) linked to platelet activation, which may help develop better treatments for serious infections.
This study looks at whether platelet transfusions help patients with sepsis and very low platelet counts recover better. If you or your loved one had sepsis, a low platelet count, and were in the ICU for at least two days, this trial may be relevant.
Hear when a new Sepsis Cardiac Insufficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.